免疫检查点抑制剂在局部晚期食管癌辅助治疗中的应用  

Application of immune checkpoint inhibitors in adjuvant therapy for locally advanced esophageal cancer

作　　者：龙杏林 谢颂平[1] 刘高利[1] 张文涵 黄杰[1] LONG Xinglin;XIE Songping;LIU Gaoli;ZHANG Wenhan;HUANG Jie(Dept.of Thoracic Surgery,Renmin Hospital of Wuhan University,Wuhan 430060,Hubei,China)

机构地区：[1]武汉大学人民医院胸外科,湖北武汉430060

出　　处：《武汉大学学报（医学版）》2024年第1期54-59,共6页Medical Journal of Wuhan University

摘　　要：食管癌是常见且预后不良的恶性肿瘤之一,就诊时多已处于晚期或局部晚期阶段。新辅助化疗或放化疗联合手术治疗对局部晚期患者的预后有所改善,但总体疗效仍不理想。为进一步改善患者预后,免疫检查点抑制剂被应用于新辅助治疗,其中免疫检查点抑制剂联合化疗以及免疫检查点抑制联合放化疗是目前常用的方案。上述两种方案的优劣仍存在争议。本文就免疫检查点抑制剂在局部晚期食管癌辅助治疗中的应用进行综述,为局部晚期食管癌治疗方案的选择提供参考。Esophageal cancer is one of the common malignant tumors with a poor prognosis,and most patients are diagnosed at the advanced or locally advanced stage.Neoadjuvant chemotherapy or chemoradiotherapy combined with surgery has improved the prognosis of patients with locally advanced disease,but the overall efficacy is still not ideal.To further improve the prognosis of patients,immune checkpoint inhibitors have been applied in neoadjuvant treatment,among which immune checkpoint inhibitors combined with chemotherapy or chemoradiotherapy are commonly used.The advantages and disadvantages of these two schemes are still controversial.This article reviews the application of immune checkpoint inhibitors in the neoadjuvant treatment of locally advanced esophageal cancer,providing a reference for the selection of treatment options for locally advanced esophageal cancer.

关 键 词：局部晚期食管癌 新辅助治疗 辅助治疗 化疗 免疫治疗 

分 类 号：R453.9[医药卫生—治疗学]